Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)
Status:
Recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
Triple blinded, phase III randomized controlled trial with parallel groups (200mg of
hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and
efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Respiratory Diseases, Mexico